Skip Ribbon Commands
Skip to main content

Prof Hui Kam Man

Prof Hui Kam Man

​​PhD,FRCPath

Profile

Professor Hui Kam Man is currently serving as Deputy Group Director (Translational Research) at SingHealth.  He is also a Principal Investigator at the Division of Cellular and Molecular Research, National Cancer Centre Singapore.  In addition, he holds Adjunct Professorships with the Program in Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School and the Dept of Biochemistry, Yong Loo Lin School of Medicine.  Besides being a Joint Research Director at the Institute of Molecular and Cell Biology (IMCB), Prof. Hui also holds an Adjunct Senior Investigator position at the Singapore BioImaging Consortium (SBIC), A*STAR. 

Prof. Hui, a Singaporean, received his BSc and MSc from the Dept of Bacteriology & Public Health, Washington State University, Pullman, USA and his PhD in Immunology, Northwestern University School of Medicine, Chicago, U.S.A.  Prior to Singapore, Prof. Hui was employed at the Royal London Hospital, Whitechapel Road, London; and as a scientific member at the MRC National Institute for Medical Research, Mill Hill, London, United Kingdom.  Prof Hui was awarded the Fellowship of The Royal College of Pathologists, FRCPath (UK) in 2001 and the Singapore National Science Award (now the President's Science Award) in 1996 for his work in cancer genes and therapy.

Education

  • Fellow, The Royal College of Pathologists, FRCPath (UK), 2001
  • Ph.D, Northwestern University School of Medicine, 1982;
  • M.Sc, Washington State University, 1978;
  • B.Sc, Washington State University, 1976;

Professional Appointments and Committee Memberships

Awards

  • 1966 National Science Award, Singapore
  • 2007 SingHealth GCEO Excellence Award (Research)

Research Interests

  • Primary liver cancer is the fifth most common cancer worldwide and hepatocellular carcinoma (HCC) accounts for over 85% of all primary liver cancers and hence, HCC is a worldwide health threat. We employ unbiased genome-wide strategies to survey relevant human HCC tissues to identify key molecular probes and genes/pathways that are altered in HCC and to explore how changes in these genes and gene regulation affect the carcinogenesis of HCC in order to learn how to manipulate these pathways to combat HCC. We have systematically gathered molecular evidence and provided clinical corroboration of these data to discover molecular biomarkers that, independently from clinical risk factors, can provide clinically meaningful avenues for designing strategies to decipher the underlying molecular networks leading to HCC, to diagnosis early stages of HCC and to predict treatment outcomes.

Publications

  • CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling. Chen J, Rajasekaran M, Xia H, Kong SN, Deivasigamani A, Sekar K, Gao H, Swa HL, Gunaratne J, Ooi LL, Xie T, Hong W, Hui KM. EMBO J. 2018 Oct 15; 37(20).
  • Insights into the etiology-associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas. Seshachalam VP, Sekar K, Hui KM. J Gastroenterol Hepatol. 2018 Dec; 33(12):2037-2047.
  • Molecular targets and anti-cancer potential of escin. Cheong DHJ, Arfuso F, Sethi G, Wang L, Hui KM, Kumar AP, Tran T. Cancer Lett. 2018 May 28; 422:1-8.
  • NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. Wang Y, Tan PY, Handoko YA, Sekar K, Shi M, Xie C, Jiang XD, Dong QZ, Goh BKP, Ooi LL, Gao Z, Hui KM. Int J Cancer. 2019 Jan 17.
  • Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. Anh Tuan Nguyen, Joanne Chia, Manon Ros, Kam Man Hui, Frederic Saltel, Frederic Bard. Cancer Cell. 2017; 32(5):639-653.e6.
  • Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM. Cell Death Discov. 2017 Sep 11;3:17058.
  • pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. Xia H, Li F, Hu X, Park W, Wang S, Jang Y, Du Y, Baik S, Cho S, Kang T, Kim DH, Ling D, Hui KM, Hyeon T (Joint Corresponding Authors). ACS Cent Sci. 2016 Nov 23;2(11):802-811.
  • The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL, Hong W, Hui KM. Gut 2016 Sep;65(9):1522-34.
  • Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. Ekta Khattar, Pavanish Kumar, Chia Yi Liu, Semih Can Akıncılar, Anandhkumar Raju, Manikandan Lakshmanan, Julien Jean Pierre Maury, Yu Qiang, Shang Li, Ern Yu Tan, Kam M. Hui, Ming Shi, Yuin Han Loh, and Vinay Tergaonkar. J Clin Invest. 2016 Oct 3;126(10):4045-4060.
  • EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma. Hongping Xia, Chen Jianxiang, Ming Shi, Hengjun Gao, Sekar Karthik, Seshachalam Veerabrahma Pratap, London Lucien P.J. Ooi, and Kam M. Hui. Journal of Hepatology. 2015 Oct;63(4):863-73.

Research Trials

  • Updated on